Evidence map›Paper›PMID 33999936›Full record

ArticlePloS one2021

MADRID+90 study on factors associated with longevity: Study design and preliminary data.

Miguel A Fernández-Blázquez, Teodoro Del Ser, Belén Frades-Payo, Marina Ávila-Villanueva, Meritxell Valentí-Soler, María T Benítez-Robredo, Antonio Bermejo-Aguña, Eduardo J Pedrero-Pérez, Javier Quilis-Sancho, Ana B Pastor and 6 more

Open access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Miguel A Fernández-BlázquezAlzheimer Disease Research Unit, CIEN Foundation, Carlos III Institute of Health, Queen Sofía Foundation Alzheimer Center, Madrid, Spain.ORCID 0000-0002-9820-8699
Teodoro Del SerAlzheimer Disease Research Unit, CIEN Foundation, Carlos III Institute of Health, Queen Sofía Foundation Alzheimer Center, Madrid, Spain.ORCID 0000-0001-9806-7083
Belén Frades-PayoAlzheimer Disease Research Unit, CIEN Foundation, Carlos III Institute of Health, Queen Sofía Foundation Alzheimer Center, Madrid, Spain.
Marina Ávila-VillanuevaAlzheimer Disease Research Unit, CIEN Foundation, Carlos III Institute of Health, Queen Sofía Foundation Alzheimer Center, Madrid, Spain.
Meritxell Valentí-SolerAlzheimer Disease Research Unit, CIEN Foundation, Carlos III Institute of Health, Queen Sofía Foundation Alzheimer Center, Madrid, Spain.
María T Benítez-RobredoEvaluation and Quality Department, Madrid Salud, Madrid City Council, Madrid, Spain.
Antonio Bermejo-AguñaMunicipal Statistics Service, S.D.G. for Statistics, Madrid City Council, Madrid, Spain.
Eduardo J Pedrero-PérezEvaluation and Quality Department, Madrid Salud, Madrid City Council, Madrid, Spain.ORCID 0000-0002-3940-5609
Javier Quilis-SanchoAlzheimer Disease Research Unit, CIEN Foundation, Carlos III Institute of Health, Queen Sofía Foundation Alzheimer Center, Madrid, Spain.
Ana B PastorAlzheimer Disease Research Unit, CIEN Foundation, Carlos III Institute of Health, Queen Sofía Foundation Alzheimer Center, Madrid, Spain.
Concepción Fernández-GarridoEvaluation and Quality Department, Madrid Salud, Madrid City Council, Madrid, Spain.
Sara Morales-AlonsoEvaluation and Quality Department, Madrid Salud, Madrid City Council, Madrid, Spain.
José M Diaz-OlallaEvaluation and Quality Department, Madrid Salud, Madrid City Council, Madrid, Spain.
Nadine Correia SantosLife and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal.ORCID 0000-0001-8110-7173
Fernando MaestúDepartment of Experimental Psychology, Complutense University of Madrid (UCM), Pozuelo de Alarcón, Madrid, Spain.
Jaime Gómez-RamírezAlzheimer Disease Research Unit, CIEN Foundation, Carlos III Institute of Health, Queen Sofía Foundation Alzheimer Center, Madrid, Spain.
Fundacion Centro De Investigacion De Enfermedades Neurologicas · ESUniversidad Complutense de Madrid · ESMadrid Health Service · ESUniversity of Minho · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The progressive aging of the population represents a challenge for society. In particular, a strong increase in the number of people over 90 is expected in the next two decades. As this phenomenon will lead to an increase in illness and age-related dependency, the study of long-lived people represents an opportunity to explore which lifestyle factors are associated with healthy aging and which with the emergence of age-related diseases, especially Alzheimer's type dementia. The project "Factors associated with healthy and pathologically aging in a sample of elderly people over 90 in the city of Madrid" (MADRID+90) brings together a multidisciplinary research team in neurodegenerative diseases that includes experts in epidemiology, neurology, neuropsychology, neuroimaging and computational neuroscience. In the first phase of the project, a stratified random sampling was carried out according to the census of the city of Madrid followed by a survey conducted on 191 people aged 90 and over. This survey gathered information on demographics, clinical data, lifestyles and cognitive status. Here, the main results of that survey are showed. The second phase of the project aims to characterize individual trajectories in the course of either healthy and pathological aging, from a group of 50 subjects over 90 who will undergo a comprehensive clinical examination comprised of neurological and cognitive testing, MRI and EEG. The ultimate goal of the project is to characterize the biophysical and clinical profiles of a population that tends to receive little attention in the literature. A better understanding of the rapidly increasing group of nonagenarians will also help to design new policies that minimize the impact and future social and economic consequences of rapidly aging societies.

Indexed as

Alzheimer DiseaseElectroencephalographyHealth StatusLongevityMagnetic Resonance ImagingAged, 80 and overFemaleFollow-Up StudiesHumansMaleMulticenter Studies as TopicObservational Studies as TopicPreliminary Data

Identifiers

PMID33999936
PMCPMC8128242
OpenAlexW3163754658

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.